Grapefruit USA (OTCQB: GPFT) understands that humans aren’t the only ones who may benefit from all that cannabidiol (“CBD”) has to offer and is positioning in a rapidly growing market. The pet CBD industry has experienced significant growth over the last several years, with the Brightfield Group projecting an expected market valuation of more than $1.7 billion by 2025 (https://cnw.fm/drv6i). Grapefruit is leveraging its expertise in the space with the launch of a new USDA-certified organic CBD pet tincture. “We understand that pet owners are now demanding organic, plant-based, natural remedies to keep their furry family members calm and in good health, and avoid the potential negative side effects of generic, synthetic pet medications,” a recent article quotes Bradley Yourist, co-founder and CEO of GPFT, commenting on the product launch. “Grapefruit’s new Pet CBD Tincture meets this pet-owner market demand because it is derived from hemp grown right here in the U.S., and each batch is lab tested for purity. . . . Our commitment to obtain the USDA-certified organic seal clearly demonstrates GPFT’s continued commitment to creating the best high-quality, safe and effective CBD products for our customers, be they human, feline, canine or otherwise. Our pets deserve the same relief that their owners have experienced with our other CBD products, such as our THC-free, hemp-derived CBD Hourglass time-release topical relief cream.”
To view the full article, visit https://cnw.fm/iHzIv
About Grapefruit USA Inc.
Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. To find out more about the company, please visit www.GrapefruitBlvd.com.
NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://cnw.fm/GPFT
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
